Nexalin reports study shows brain stimulation device improved chronic insomnia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
April 28, 2026 9:15 AM EDTPublication reports statistically significant improvement in sleep quality following treatment with Nexalins 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group
Neuroimaging data provides mechanistic support for Nexalins proprietary DIFS technology and further validates the Companys advanced non-pharmacologic treatment strategy for mental health issues
Houston, TX, April 28, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the Company or Nexalin), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the brain, today announced the online publication of a peer-reviewed study in Psychotherapy and... More
